Entero Therapeutics (NASDAQ:ENTO) (NASDAQ: ENTO) is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for rare gastrointestinal diseases. The company’s flagship product, RELiZORB®, is an innovative pre‐validated enzyme cartridge designed to hydrolyze fats in enteral nutrition formulas for patients with exocrine pancreatic insufficiency and related malabsorption conditions. By integrating this cartridge into standard feeding sets, Entero aims to improve nutrient absorption and quality of life for individuals dependent on tube feeding.
In addition to its marketed offering, Entero maintains a pipeline of investigational therapies targeting critical unmet needs in gastroenterology. Early‐stage programs under investigation include potential treatments for short bowel syndrome, chemotherapy‐induced diarrhea, and other orphan indications characterized by compromised nutrient absorbance and gastrointestinal dysfunction. These development efforts leverage the company’s expertise in enzyme biology and drug delivery systems to address complex digestive disorders that lack effective therapeutic options.
Founded in 2012 and headquartered in Cambridge, Massachusetts, Entero Therapeutics serves patients primarily in the United States, with strategic initiatives underway to expand its commercial presence in Europe and select global markets. The company collaborates with leading clinical centers and nutrition support providers to facilitate access to its technologies and generate real‐world evidence that underscores product benefits. Such partnerships bolster Entero’s commitment to patient‐centric care and support its efforts to secure reimbursement pathways for specialty therapies.
Entero’s leadership team combines seasoned professionals from the pharmaceutical and biotechnology sectors, bringing deep experience in rare disease drug development, regulatory strategy, and commercial execution. Under the direction of its executive management, the company remains dedicated to advancing its platform of enzyme‐based and small‐molecule therapies. Through ongoing clinical research and strategic alliances, Entero Therapeutics strives to transform standard-of-care approaches for patients facing life‐altering gastrointestinal conditions.
